Pre-Implantation Genetic Diagnosis (PGD) is the genetic profiling of embryos prior to implantation (as a form of embryo profiling), and sometimes even of oocytes prior to fertilization.
This report contains market size and forecasts of Pre-Implantation Genetic Diagnosis (PGD) in Global, including the following market information:
Global Pre-Implantation Genetic Diagnosis (PGD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Pre-Implantation Genetic Diagnosis (PGD) market was valued at 104.6 million in 2021 and is projected to reach US$ 138.6 million by 2028, at a CAGR of 4.1% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Chromosomal Abnormalities Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pre-Implantation Genetic Diagnosis (PGD) include Roche, Genea Limited, Quest Diagnostics, Illumina, Inc., Natera, Inc., Cooper Medical, Inc., LabCorp, California Pacific Medical Center (CPMC) and Thermo Fisher Scientific Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pre-Implantation Genetic Diagnosis (PGD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pre-Implantation Genetic Diagnosis (PGD) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Pre-Implantation Genetic Diagnosis (PGD) Market Segment Percentages, by Type, 2021 (%)
Chromosomal Abnormalities
X-linked Diseases
Freeze Embryo Testing
Aneuploidy Screening
HLA
Others
Global Pre-Implantation Genetic Diagnosis (PGD) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Pre-Implantation Genetic Diagnosis (PGD) Market Segment Percentages, by Application, 2021 (%)
Stem Cell Therapy
IVF Prognosis
Late-Onset Genetic Disorders
Inherited Genetic Disease
Others
Global Pre-Implantation Genetic Diagnosis (PGD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Pre-Implantation Genetic Diagnosis (PGD) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pre-Implantation Genetic Diagnosis (PGD) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Pre-Implantation Genetic Diagnosis (PGD) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Genea Limited
Quest Diagnostics
Illumina, Inc.
Natera, Inc.
Cooper Medical, Inc.
LabCorp
California Pacific Medical Center (CPMC)
Thermo Fisher Scientific Inc.
IGENOMIX
Reproductive Genetic Innovations
CombiMatrix